UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
November 14, 2024 17:00 ET
|
Tevogen Bio Inc
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogen’s success would...
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
November 14, 2024 15:49 ET
|
Tevogen Bio Inc
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm.Tevogen’s success would...
Univest Securities, LLC Announces First Closing of $30 Million Convertible Note Offering for its Client Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE)
September 12, 2024 16:30 ET
|
Univest Securities, LLC
New York, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York,...
Kane Biotech Announces Exercise of Warrants
September 12, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the exercise of an aggregate of 5 million warrants at an...
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 06, 2024 08:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals closes a $4M private placement for working capital and R&D, with stock and warrants priced at $1.38 per share.
Aduro Clean Technologies Announces Effective Date for Share Consolidation and Conversion of Class B Special Warrants
August 16, 2024 07:09 ET
|
Aduro Clean Technologies Inc.
Aduro Clean Technologies Announces Effective Date for Share Consolidation and Conversion of Class B Special Warrants
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
August 09, 2024 11:00 ET
|
Tevogen Bio Inc
Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities.
BRIGHT GREEN ANNOUNCES IT HAS OBTAINED A $3.5 MILLION FUNDING COMMITMENT UNDER AN EXISTING LINE OF CREDIT AND HAS ENGAGED AN INVESTMENT BANK TO SEEK A $15.0 MILLION DEBT FINANCING TO MOVE FORWARD WITH COMMERCIALIZATION.
August 08, 2024 16:51 ET
|
Bright Green Corporation
GRANTS, NEW MEXICO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that the Company has engaged an investment bank with...
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
July 22, 2024 08:30 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds
July 11, 2024 08:17 ET
|
Onconetix, Inc.
CINCINNATI, Ohio, July 11, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has entered into definitive agreements for the immediate...